October 2017: Bodor Laboratories’ licensee, Brickell Biotech, announces positive and statistically significant results in a confirmatory Phase 2b study of their licensed product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. [Link]
October 2017: Publication of a peer-reviewed article of potent analogues of our second generation soft corticosteroid. [Link]
March 2017: Publication of a peer-reviewed article identifying the esterase responsible for the metabolism of two soft corticosteroid drugs. [Link]
December 2015: Bodor Laboratories’ licensee Brickell Biotech obtains clinically meaningful Phase 2b study results with the novel topical soft-anticholinergic Sofpironium Bromide in patients with hyperhidrosis [Link]
October 2015: Bodor Laboratories organizes a symposium on “Retrometabolic Drug Design” at the 20th North American ISSX Conference in Orlando, FL [Link]
April 2015: Bodor Laboratories’ licensee Brickell Biotech executes an exclusive sublicense and development agreement for Sofpironium Bromide with Kaken Pharmaceutical Co., Ltd. In Japan [Link]
September 2014: Bodor Laboratories’ licensee Brickell Biotech obtains positive initial results from a Pilot Clinical Study of the novel topical soft-anticholinergic Sofpironium Bromide for the treatment of hyperhidrosis [Link]
May 2013: 9th Retrometabolism Based Drug Design and Targeting Conference in Orlando, FL
December 2012: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-anticholinergic with Brickell Biotech, Inc. for the treatment of hyperhidrosis
October 2012: Publication of the book “Retrometabolic Drug Design and Targeting” by Wiley Publishing, authored by Dr. Nicholas Bodor and Dr. Peter Buchwald [Link]
December 2011: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-steroid with Nephron Pharmaceuticals Corp. for ophthalmic use
October 2011: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-steroid with Dechra Pharmaceuticals PLC for dermatological and otic use in animals
June 2011: 8th Retrometabolism Based Drug Design and Targeting Conference in Graz, Austria
November 2011: Bodor Laboratories moves into the office space at 4400 Biscayne Boulevard in Miami, FL
May 2009: 7th Retrometabolism Based Drug Design and Targeting Conference in Orlando, FL
May 2007: 6th Retrometabolism Based Drug Design and Targeting Conference in Göd, Hungary
January 2006: Bodor Laboratories is incorporated in the state of Florida